Sheathless acoustic based flow cell sorter for enrichment of rare cells

2021 ◽  
Author(s):  
Ce Wang ◽  
Yuting Ma ◽  
Zhiguo Pei ◽  
Feifei Song ◽  
Jinfeng Zhong ◽  
...  
Keyword(s):  
1998 ◽  
Vol 37 (1-2) ◽  
pp. 11-33 ◽  
Author(s):  
Lee R. Moore ◽  
Maciej Zborowski ◽  
Liping Sun ◽  
Jeffrey J. Chalmers
Keyword(s):  

2021 ◽  
Vol 20 ◽  
pp. 153303382110342
Author(s):  
玉峰 席

Purpose: Human umbilical endothelial cells (HUVECs) have been proved to be an effective whole-cell vaccine inhibiting tumor angiogenesis. In this study, we fused HUVECs with human lung adenocarcinoma cells A549 s, aiming at preparing lung cancer vaccine to achieve dual effects of anti-tumor angiogenesis and specific immunity to tumor cells. Methods: A549 cells were induced by ethyl methane sulfonate (EMS) and 8-azaguanine (8-AG) to get hypoxanthine guanine phosphoribosyl transferase (HGPRT) auxotrophic A549 cells. Then Fused HGPRT auxotrophic A549 cells with primary HUVEC cells by combining electrofusion with polyethylene glycol (PEG). Afterward the fusion cells were screened by HAT and HT selective medium and sorted by flow cell sorter to obtain high-purity HUVEC-A549 cells. Finally, HUVEC-A549 cells were identified by karyotype analysis and western blotting. Results: The fusion efficiency of HUVEC-A549 cells prepared by combining electrofusion with polyethylene glycol (PEG) was significantly higher than that of electrofusion and PEG (43.0% vs 17.60% vs 2.71%, P < 0.05). After screened by HAT and HT selective medium and sorted by flow cell sorter, the proportion of HUVEC-A549 cells can count for 71.2% ± 3.2%. The mode of chromosomes in HUVEC-A549 cells was 68, and the chromosome was triploid. VE-cadherin and platelet endothelial cell adhesion molecule-1 (CD31) were highly expressed in HUVECs and HUVEC-A549 cells, but not in A549 cells. Conclusions: These results indicate that HUVEC-A549 cells retain the biological characteristics of human umbilical vein endothelial cells and A549 cells. It can be used in the experimental study of lung cancer cell vaccine.


2019 ◽  
Author(s):  
Yasuhiro Koh ◽  
Mio Ikeda ◽  
Shunsuke Teraoka ◽  
Masayuki Ishige ◽  
Yuu Fujimura ◽  
...  

2019 ◽  
Author(s):  
Yasuhiro Koh ◽  
Mio Ikeda ◽  
Shunsuke Teraoka ◽  
Masayuki Ishige ◽  
Yuu Fujimura ◽  
...  

Author(s):  
Lee R. Moore ◽  
Maciej Zborowski ◽  
Liping Sun ◽  
Jeffrey J. Chalmers
Keyword(s):  

2006 ◽  
Vol 78 (5) ◽  
pp. 1657-1664 ◽  
Author(s):  
Khanh C. Hoang ◽  
Dmitry Malakhov ◽  
William E. Momsen ◽  
Howard L. Brockman

Author(s):  
L.N. Moskvin ◽  
О.V. Rodinkov ◽  
А.L. Moskvin ◽  
V. Spivakovskii ◽  
A.Y. Vlasov ◽  
...  

Energies ◽  
2021 ◽  
Vol 14 (4) ◽  
pp. 1109
Author(s):  
Robert Bock ◽  
Björn Kleinsteinberg ◽  
Bjørn Selnes-Volseth ◽  
Odne Stokke Burheim

For renewable energies to succeed in replacing fossil fuels, large-scale and affordable solutions are needed for short and long-term energy storage. A potentially inexpensive approach of storing large amounts of energy is through the use of a concentration flow cell that is based on cheap and abundant materials. Here, we propose to use aqueous iron chloride as a reacting solvent on carbon electrodes. We suggest to use it in a red-ox concentration flow cell with two compartments separated by a hydrocarbon-based membrane. In both compartments the red-ox couple of iron II and III reacts, oxidation at the anode and reduction at the cathode. When charging, a concentration difference between the two species grows. When discharging, this concentration difference between iron II and iron III is used to drive the reaction. In this respect it is a concentration driven flow cell redox battery using iron chloride in both solutions. Here, we investigate material combinations, power, and concentration relations.


2021 ◽  
Author(s):  
Maximilian König ◽  
Shih-Hsuan Lin ◽  
Jan Vaes ◽  
Deepak Pant ◽  
Elias Klemm

The electrochemical CO2 reduction to oxalic acid in aprotic solvents could be a potential pathway to produce carbon-neutral oxalic acid. One of the challenges in the aprotic CO2 reduction are...


BMC Genomics ◽  
2020 ◽  
Vol 21 (S11) ◽  
Author(s):  
Adam Cornish ◽  
Shrabasti Roychoudhury ◽  
Krishna Sarma ◽  
Suravi Pramanik ◽  
Kishor Bhakat ◽  
...  

Abstract Background Single-cell sequencing enables us to better understand genetic diseases, such as cancer or autoimmune disorders, which are often affected by changes in rare cells. Currently, no existing software is aimed at identifying single nucleotide variations or micro (1-50 bp) insertions and deletions in single-cell RNA sequencing (scRNA-seq) data. Generating high-quality variant data is vital to the study of the aforementioned diseases, among others. Results In this study, we report the design and implementation of Red Panda, a novel method to accurately identify variants in scRNA-seq data. Variants were called on scRNA-seq data from human articular chondrocytes, mouse embryonic fibroblasts (MEFs), and simulated data stemming from the MEF alignments. Red Panda had the highest Positive Predictive Value at 45.0%, while other tools—FreeBayes, GATK HaplotypeCaller, GATK UnifiedGenotyper, Monovar, and Platypus—ranged from 5.8–41.53%. From the simulated data, Red Panda had the highest sensitivity at 72.44%. Conclusions We show that our method provides a novel and improved mechanism to identify variants in scRNA-seq as compared to currently existing software. However, methods for identification of genomic variants using scRNA-seq data can be still improved.


Sign in / Sign up

Export Citation Format

Share Document